By contrast, genes that do not belong to the adrenergic CRC and acquire new super-enhancers as they join the retino-sympathetic CRC induced by ATRA—RARA, MEIS1, and SOX4—have steadily rising expression levels during ATRA treatment (Fig. 7B). Here, SOX4 is linked to colorectal carcinoma.